Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Publikation

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Wissenschaftlicher Artikel/Review - 02.04.2022

Rischin Danny, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Ishak Wan Zamaniah Wan, Hong Ruey-Long, Mendoza René Gonzalez, Jia Liyi, Chirovsky Diana, Norquist Josephine, Jin Fan, Burtness Barbara

Zitation

Rischin D, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Hong R, Mendoza R, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 2022; 128:105815.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Oral Oncol 2022; 128

Veröffentlichungsdatum

02.04.2022

eISSN (Online)

1879-0593

Seiten

105815

Kurzbeschreibung/Zielsetzung

To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the phase 3 KEYNOTE-048 trial (NCT02358031).